Impaired Neutralizing Antibody Activity against B.1.617.2 (Delta) after Anti-SARS-CoV-2 Vaccination in Patients Receiving Anti-CD20 Therapy (original) (raw)
Longitudinal analysis of antibody trajectories and humoral responses to a third dose of mRNA vaccines against SARS-CoV-2 in patients with a history of anti-CD20 therapy (RituxiVac 2.0)
Cornelia Staehelin
2021
View PDFchevron_right
Strong Humoral but Not Cellular Immune Responses against SARS-CoV-2 in Individuals with Oncohematological Disease Who Were Treated with Rituximab before Receiving a Vaccine Booster
Mayte Coiras
Cancers
View PDFchevron_right
Impact of Treatment with Anti-CD20 Monoclonal Antibody on the Production of Neutralizing Antibody Against Anti–SARS-CoV-2 Vaccination in Mature B-Cell Neoplasms
Tohru Inaba
Infection and Drug Resistance
View PDFchevron_right
B cell numbers predict humoral and cellular response upon SARS-CoV-2 vaccination among patients treated with rituximab
Gabriella Guerra
2021
View PDFchevron_right
Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice
Alexander Pang
Military Medical Research, 2021
View PDFchevron_right
Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma
Maryam Azeem
Journal of Clinical Oncology
View PDFchevron_right
Promising efficacy of following a third dose of mRNA SARS-CoV-2 vaccination in patients treated with anti-CD20 antibody who failed 2-dose vaccination
Naomi Kiyota
medRxiv (Cold Spring Harbor Laboratory), 2022
View PDFchevron_right
Anti-SARS-CoV-2 IgG and Neutralizing Antibody Levels in Patients with Past COVID-19 Infection: A Longitudinal Study
Serhat Sirekbasan
Balkan Medical Journal
View PDFchevron_right
Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study
Efstathios Kastritis
Blood Advances, 2021
View PDFchevron_right
Longitudinal data on humoral response and neutralizing antibodies against SARS-CoV-2 Omicron BA.1 and subvariants BA.4/5 and BQ.1.1 after COVID-19 vaccination in cancer patients
Celine Lugnier
Journal of Cancer Research and Clinical Oncology
View PDFchevron_right
Limited increase in antibody titers following mRNA SARS-CoV-2 vaccination for more than 3 years after final dose of anti-CD20 antibody
Naomi Kiyota
International Journal of Hematology, 2022
View PDFchevron_right
Preclinical Efficacy of IMM-BCP-01, a Highly Active Patient-Derived Anti-SARS-CoV-2 Antibody Cocktail
Nirja Patel
2021
View PDFchevron_right
High levels of anti–SARS-CoV-2 IgG antibodies in previously infected patients with cancer after a single dose of BNT 162b2 vaccine
Manfred Mitterer
European Journal of Cancer, 2021
View PDFchevron_right
Assessment of antibody dynamics and neutralizing activity using serological assay after SARS-CoV-2 infection and vaccination
Faith Jessica Paran
PLOS ONE, 2023
View PDFchevron_right
Assessing SARS-CoV-2 Neutralizing Antibodies after BNT162b2 Vaccination and Their Correlation with SARS-CoV-2 IgG Anti-S1, Anti-RBD and Anti-S2 Serological Titers
Angélica Ramos
Diagnostics, 2022
View PDFchevron_right
Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies
Rafi Ahmed
Cancer Research Communications
View PDFchevron_right
Selective suppression of de novo SARS-CoV-2 vaccine antibody responses in patients with cancer on B cell–targeted therapy
Narendranath Epperla
JCI Insight
View PDFchevron_right
Clinical, laboratory, and temporal predictors of neutralizing antibodies to SARS-CoV-2 after COVID-19
Lichen Jing
View PDFchevron_right
Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study
Efstathios Kastritis
Cancers
View PDFchevron_right
Humoral and Cellular Responses to SARS-CoV-2 Vaccines Before and After Chimeric Antigen Receptor-Modified T Cell Therapy
Atif Bhatti
Blood Advances
View PDFchevron_right
Longitudinal efficacy and toxicity of SARS-CoV-2 vaccination in cancer patients treated with immunotherapy
Andrzej Chruscinski
Cell Death and Disease, 2023
View PDFchevron_right
COVID‐19 elicits an impaired antibody response against SARS‐CoV‐2 in patients with haematological malignancies
Ilaria Romano
British Journal of Haematology, 2021
View PDFchevron_right
SARS-CoV-2 antibody response after BBIBP-CorV (Sinopharm) vaccination in cancer patients: A case-control study
Mahin jamshidi
Frontiers in Medicine, 2023
View PDFchevron_right
Promising Efficacy of a Third Dose of mRNA SARS-CoV-2 Vaccination in Patients Treated with Anti-CD20 Antibody Who Failed 2-Dose Vaccination
Naomi Kiyota
Vaccines
View PDFchevron_right
Breadth and function of antibody response to acute SARS-CoV-2 infection in humans
jia jan
2020
View PDFchevron_right
A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity
Carole Pelissier
Cellular & Molecular Immunology, 2021
View PDFchevron_right
Anti-SARS-CoV-2 antibody immunoreactivity profiles during COVID-19 recurrence
Isac Moulaz
Revista Da Sociedade Brasileira De Medicina Tropical, 2022
View PDFchevron_right
Rituximab Impairs B Cell Response But Not T Cell Response to COVID ‐19 Vaccine in Autoimmune Diseases
Julien Henry
Arthritis & Rheumatology, 2021
View PDFchevron_right
Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID19 Patients
Brett Ransegnola
Journal of Clinical Microbiology, 2020
View PDFchevron_right
Antibodies against SARS-CoV-2 Time Course in Patients and Vaccinated Subjects: An Evaluation of the Harmonization of Two Different Methods
Ruggero Dittadi
Diagnostics, 2021
View PDFchevron_right
Control of SARS-CoV-2 infection in rituximab-treated neuroimmunological patients
Julian Schulze zur Wiesch
Journal of Neurology
View PDFchevron_right
Long-term antibody-response monitoring following primary exposure to SARS-COV-2 and afterward mRNA COVID-19 vaccination: A case report
Milena Todorovic
Vojnosanitetski pregled, 2021
View PDFchevron_right
A longitudinal study of SARS-CoV-2 infected patients shows high correlation between neutralizing antibodies and COVID-19 severity
Sylvie Pillet
medRxiv, 2020
View PDFchevron_right
Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern
Blair Merrick
Nature Microbiology
View PDFchevron_right